AbiertoNCT06362369⚑ Reportar un problema con este anuncio

Estudio de 7HP349 oral (Alintegimod) en combinación con ipilimumab seguido de monoterapia con nivolumab

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

Abierto a todos los participantes calificados

Fase

PHASE1, PHASE2

Inscripción

126 (estimado)

Rango de edad

18 Years to —

Sexo

ALL

Resumen

An open-label Phase 1b dose escalation followed by a randomized Phase 2a comparison, evaluating oral alintegimod alone and combined with ipilimumab, followed by nivolumab monotherapy, in locally advanced or metastatic solid tumors.

Mostrando el original en inglés

Afecciones estudiadas

Advanced Solid TumorMelanomaPleural MesotheliomaRenal Cell CarcinomaMSI-HighMismatch Repair DeficiencyColorectal CancerHepatocellular CarcinomaNon Small Cell Lung Cancer

Patrocinadores

7 Hills Pharma, LLCPrincipal

Ubicaciones del estudio

University of Colorado Cancer Center

Aurora, Colorado

Sapna Patel, MD, PRINCIPAL_INVESTIGATOR

Florida Cancer Specialists

Lake Mary, Florida

Verificando el contacto del sitio

Dartmouth Hitchcock

Lebanon, New Hampshire

Konstantin H Dragnev, MD, PRINCIPAL_INVESTIGATOR

Brown University Health Cancer Institute

Providence, Rhode Island

Cancer Institute Clinical Research Nurse, CONTACT

MD Anderson Cancer Center

Houston, Texas

Apostolia-Maria Tsimberidou, MD, PhD, PRINCIPAL_INVESTIGATOR